ZURA BIO LIMITED Foreign Pre-Tax Income
ZURA BIO LIMITED (ZURA) reported Foreign Pre-Tax Income of $965.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign · last filed 2026-03-19
- ZURA BIO LIMITED income (loss) from continuing operations before income taxes, foreign for fiscal 2025 was $965.00K.
- ZURA BIO LIMITED income (loss) from continuing operations before income taxes, foreign for fiscal 2024 was -$10.57M.
- ZURA BIO LIMITED income (loss) from continuing operations before income taxes, foreign for fiscal 2023 was -$23.72M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Foreign 11 month | Income (Loss) from Continuing Operations before Income Taxes, Foreign 12 month |
|---|---|---|
| 2025-12-31 | $965.00K 10-K · filed 2026-03-19 | |
| 2024-12-31 | -$10.57M 10-K · filed 2026-03-19 | |
| 2023-12-31 | -$23.72M 10-K · filed 2025-03-25 | |
| 2022-12-31 | -$12.08M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |